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Abstract Viozan TM (sibenadet HCI,AR-C68397AA) is a novel dual D 2 dopamine receptor, 132-adrenoceptor agonist that 
has been investigated for efficacy in alleviating the symptoms of chronic obstructive pulmonary disease (COPD).The slowly 
progressive nature of this disease means that patients will require ongoing therapeutic management for many years, or 
even decades.With such long-term treatment, the safety profile of new agents will be of paramount importance. 
As part of the large-scale assessment of sibenadet, a 12-month safety study has been conducted. Following completion of 
a 2-week baseline period, 435 adults with stable, symptomatic, smoking-related COPD were randomized to receive either 
500 I~g sibenadet or placebo delivered via pressurized metered dose inhaler (pMDI), three times daily for 52weeks. 
Sibenadet herapy was generally well tolerated, with the only notable differences een in the incidence of tremor and taste 
of treatment (16-9% vs. 4. I% and 14.5% vs. 4-I% in the sibenadet and placebo groups respectively). There were a total 
of 79 patients with serious adverse events (SAEs), 43 (14.8%) in the sibenadet pMDI group and 36 (24.8%) in the placebo 
group. No clinically significant abnormal laboratory values or overall differences between treatment groups were noted. 
Similarly, there were no clinically significant differences between the two treatment groups for cardiac variables, or in vital 
signs.The secondary variables showed no notable differences with respect to lung function, exacerbations or health-related 
quality of life. Due to the effective 132-agonist properties, patients in the sibenadet group did, however, report reduced 
rescue medication usage at all timepoints. 
While the results of this study show that, overall, sibenadet therapy was well tolerated, the lack of sustained benefit 
reported in large-scale clinical efficacy studies means that sibenadet development will not be continued. 
© 2003 Elsevier Science Ltd 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is a 
disease characterized by airflow obstruction caused by 
chronic bronchitis, emphysema or a combination of both 
conditions (I).The loss of alveolar gas exchange surface 
area and progressive symptoms (primarily breathless- 
ness, cough and sputum) ultimately reduce physical 
activities and impair social and professional interactions, 
which in turn can lead to a sense of isolation, loneliness, 
and often depression (2). 
The disease course of COPD is extremely slow, 
progressing over many years. Although smoking cessation 
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slows further loss of lung function, no therapeutic 
intervention has yet been shown to modify the long- 
term decline in lung function. Alleviating patient 
symptoms is therefore a key objective in patient 
management. While bronchodilator therapies remain 
central to the symptomatic ontrol of COPD, their use 
can have only limited effect in a disease characterized by 
irreversible airways obstruction. Although inhaled 
corticosteroids are also commonly used in COPD 
patients, clinical benefit in patients with mild to moderate 
COPD has not been demonstrated (3). Relief of patient 
symptoms is therefore limited with current therapeutic 
options and new, highly effective agents are urgently 
required.The safety of new agents will be of paramount 
importance in order to meet the requirement for long- 
term relief of COPD symptoms. 
Viozan TM (sibenadet HCI, AR-C68397AA) is the first 
dual D 2 dopamine receptor, ~2-adrenoceptor agonist, 
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developed for the treatment of COPD symptoms.This 
novel agent combines the conventional approach of 
bronchodilation (through.[~2-adrenoceptor agonism), 
with sensory nerve modulation in the lung (an effect of 
D 2 dopamine receptor agonism). Inhibition of sensory 
signalling from the lung may alter the perception of lung 
irritation, and thus alleviate COPD symptoms (4,5). 
In vivo evaluation of sibenadet has confirmed the ability 
to inhibit reflex tachypnoea, cough and mucus 
production in animal models of COPD symptoms (6). 
The results of a I-year study designed to assess the 
safety and tolerability of sibenadet are reported here. 
This placebo-controlled, multicentre trial represents one 
of four large-scale clinical studies designed to evaluate 
the full clinical potential of this new therapeutic agent. 
METHODS 
Patient population 
Male and female patients with stable, uncomplicated 
COPD (with symptoms for at least 2years), aged 
40-80 years with a smoking history of at least 15 pack- 
years, a forced expiratory volume in one second/forced 
vital capacity (FEVJFVC) ratio of < 70%, and an FEV I 
20-70% of the predicted normal range, were eligible for 
entry into this study. 
Patients not eligible for the study included those with 
other significant diseases, evidence of an exacerbation in 
the previous 6 weeks, previous participation in a clinical 
study of sibenadet, participation in any clinical study in 
the previous 3 months, laboratory abnormalities or use 
of disallowed medication (long-acting bronchodilators, 
anticholinergics, leukotriene antagonists, dopamine 
agonists or antagonists, [3-adrenoceptor blockers). 
Patients were allowed to continue using inhaled 
anticholinergic agents, mucolytics, methylxanthines and 
corticosteroids, provided that the dose remained 
constant throughout he study. 
Study design 
This was a double-blind, placebo-controlled study 
conducted in 44 centres in the U.S.A~ Eligible patients 
were enrolled on a 2-week baseline assessment period. 
Disallowed medication was withdrawn, and salbutamol 
100 ~tg pressurized metered-dose inhalers (pMDIs) were 
supplied for use as rescue medication at a dose of two 
actuations when required. All patients were counselled 
concerning the benefits of smoking cessation. At the end 
of the baseline period, patients who had completed their 
diary card correctly and had not experienced a COPD 
exacerbation were randomized to receive either 500 I~g 
sibenadet or placebo pMDI three times daily 
(ex-actuator) for a total of 52 weeks. Randomization was 
biased 2:1, sibenadet:placebo.The dose of sibenadet was 
chosen on the basis of two earlier studies (7,8). Patients 
returned to the clinic for assessment after I week of 
treatment, 3weeks later and subsequently at 8-week 
intervals.At he end of the treatment period, sibenadet 
and placebo inhalers were withdrawn, and patients were 
required to continue using only rescue medication for a 
further 4-week follow-up period, after which one final 
clinic visit was made. Diary cards were completed by 
patients throughout the study to record use of study and 
rescue medication, changes in concomitant medication 
and adverse events (AEs). Compliance with treatment 
protocol was assessed by checking diary cards, and 
weighing pMDIs to estimate the amount of drug 
dispensed. 
The study was performed in accordance with the 
principles stated in the Declaration of Helsinki and 
approved by ethics committees at each centre. 
Primary outcome measure 
The primary outcome measure was the incidence of AEs 
over the 52-week treatment period in the sibenadet 
treatment group, compared with placebo. An adverse event 
was defined as the development of an undesirable medical 
condition or the deterioration of a pre-existing medical 
condition. 
AEs were recorded in diary cards and at each clinic visit. 
Details of symptoms, onset, outcome, maximum intensity, 
seriousness, action taken, and causality rating were 
recorded. All events were followed up to resolution (either 
full reversion, or reversion to a point where no further 
improvement was apparent). AEs included clinically relevant 
changes from baseline in laboratory data; results at physical 
examination; vital signs; symptom severity or frequency; use 
of rescue medication; COPD exacerbations; and lung 
function. In addition, Holter ECGs were performed at three 
clinic visits to identify any arrhythmogenic effects of the 
study drug. 
Serious adverse events (SAEs) were defined as events 
that were life threatening, causing death, requiring 
hospitalization, or causing persistent or significant disability. 
Secondary outcome measures 
Changes from baseline in the sibenadet and placebo 
groups were determined for the following efficacy 
variables and were considered as secondary outcome 
measures in this study. However, clinically significant 
deleterious changes in these variables were also classed 
as AEs and therefore included in the primary data. 
Lung function 
Lung function was assessed using spirometry (FEV I and 
FVC) at each clinic visit. Measurements were taken for at 
least three separate manoeuvres. Where possible, 
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spirometry was conducted at the same time of day 
(+ 2 hours), and using the same spirometer. 
COPD exacerbation 
Exacerbations were defined as worsening symptoms of 
COPD requiring drug therapy in addition to study drug, 
rescue medication and doses of concomitant COPD 
medications. The incidence, start and stop dates and 
severity of exacerbations of COPD were documented in 
the case report form as AEs.At every clinic visit patients 
were asked if they had experienced an exacerbation 
since their last visit. The end date was, in the 
investigator's opinion, the point at which the patient 
returned to the same level of COPD symptoms as they 
were experiencing prior to their exacerbation, or where 
there was no further improvement of the patient's 
COPD symptoms following the exacerbation. 
Health-related quality of life (HRQL) 
HRQL was assessed using the disease-specific St 
George's Respiratory Questionnaire (SGRQ) (9), and the 
generic SF-36 (10). Questionnaires were completed at 
the end of the baseline period, at four clinic visits during 
the treatment period and at the end of the follow-up 
period. Data were analysed for changes from baseline. 
Use of rescue medication 
Use of rescue medication was recorded daily by patients 
in diary cards and analysed for change from baseline. 
Statistical analyses 
As the study was not hypothesis based, the primary and 
secondary endpoints contributed to the objectives of 
the study, which was to assess the long-term effects of 
the treatments on both safety and efficacy parameters. 
As the study contained a placebo arm, comparisons were 
made between the two treatment groups. For the 
comparison of the active treatment group to placebo, an 
analysis of variance model with baseline as the covariate 
was used for analyses of lung function, quality of life and 
rescue medication usage and Fisher's exact test was used 
for analysis of the incidence of exacerbations. Data are 
presented as standard summary statistics (e.g. mean, 
standard deviation/standard error for continuous data 
and frequencies and proportions for categorical data) 
and corresponding 95% confidence intervals where 
appropriate. 
Patients who received at least one dose of study drug 
were included in the analysis and summaries included 
patients according to the treatment they actually 
received.The incidence of AEs was determined over the 
entire 52-week treatment period for the sibenadet 
treatment group and compared with placebo. In addition, 
data were summarized for the baseline period, for weeks 
0-4 of the treatment period, for 8-week periods up to 
the end of the treatment period, and for the follow-up 
period. AEs were summarized in terms of maximum 
intensity, causality, and seriousness. In addition, SAEs and 
AEs leading to discontinuation from the study were 
determined separately. 
It was aimed to randomize a minimum of 400 patients 
into the study. Even assuming a withdrawal rate of 
between 25% and 50%, this would provide sufficient 
information on the long-term safety profile of sibenadet, 
whilst adhering to regulatory guidelines. 
RESULTS 
Patient demographics 
A summary of patient disposition is outlined in Figure I; 
64% and 69% of patients randomized to receive 
sibenadet or placebo therapy respectively, completed the 
trial.The primary reasons for discontinuation during the 
study were an AE, withdrawal of consent, or deteriora- 
tion of condition. 
Patient demographics are outlined in Table I. No 
notable differences between treatment groups for the 
key demographic and baseline parameters were seen. All 
randomized patients were included in the safety and 
efficacy analyses (n=435). Over 80% of randomized 
patients were > 80% compliant with study medication, as 
determined from the diary cards. 
Adverse events 
A similar incidence of adverse event reporting was seen 
in both treatment groups during the treatment period; 
the proportion of patients reporting at least one AE was 
92.1% and 90.3% in the sibenadet and placebo groups 
respectively. The most frequently reported AEs were 
COPD (25.2% sibenadet, 26.9% placebo) and respiratory 
infection (18-3% sibenadet, 29.7% placebo). AEs 
occurring in >5% of patients in either group are 
summarized in Table 2. The ~32-related AEs (i.e. tremor 
and nervousness) were reported more commonly in the 
patients receiving sibenadet. 
A total of 77 (17.7%) patients discontinued the study 
due to an AE (including deaths and serious AEs). In the 
sibenadet and placebo groups, this figure was 19.3% and 
14.5% respectively. A summary of reported events is 
shown in Table 3. No difference was detected between 
the two groups with respect to time to withdrawal. 
Reporting of AEs considered to be potentially 
D2-dopamine-related (nausea, vomiting, somnolence and 
confusion) was low and no differences were seen 
between the two treatment groups. 
A total of 79 (18.2%) patients experienced an SAE 
during the treatment period: 14.8% in the sibenadet 
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n=-145 
Sibenadet 
n---290 
Completed 
r~-lO0 
Completed 
r~-187 
FIGURE I. Patient disposition. 
group and 24-8% in the placebo group. A summary of 
SAEs is shown in Table 4. 
Five deaths were reported during the study, three in the 
sibenadet group (cardiac death in two patients and 
metastatic adenocarcinoma in one patient) and two in the 
placebo group (due to liver disease and lung cancer).A drug 
relationship was consider unlikely in all cases except one 
cardiac death where a causal effect was considered possible. 
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No clinically significant abnormal laboratory values or 
differences between treatment groups were noted. 
Similarly, there were no clinically significant differences 
between the two treatment groups for cardiac variables 
(ECG variables, 24-hour Holter monitoring, or serum 
troponin T levels), or in vital signs. 
No differences in any safety parameters were seen 
between the two groups during the follow-up period. 
Outcome variables 
Lung function 
FEV I measurements showed no deterioration of lung 
function over the 52-week treatment period in patients 
receiving sibenadet (mean change from baseline 0.01 
SE + 0.02).A small reduction in lung function was een in 
the placebo group (mean change from baseline -0.03 
SE + 0"02). 
Number and duration fexacerbations 
The incidence of COPD exacerbations is shown in 
Table 5. No difference was observed between sibenadet 
and placebo at the end of the treatment period or at 
any other timepoints. No differences between the 
treatment groups were detected with regard to time to 
first COPD exacerbation or duration of COPD 
exacerbations. 
Health-related quality of life 
There were no notable differences between the treat- 
ment groups for changes from baseline in either the 
SGRQ total or individual domain scores or the SF-36 
scores. 
Rescue medication usage 
Patients receiving sibenadet reported less rescue 
medication use over the duration of the treatment 
period, and exhibited a least squares (LS) mean change 
from baseline at the end of the treatment period of 1.66 
(SE + 0.15) vs. 0"86 (SE + 0.21) for placebo patients.The 
difference in the change from baseline over the 
treatment period between the sibenadet and placebo 
groups was -0.82 (95% CI -I-32, -0"32). 
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DISCUSSION 
The I-year study of sibenadet therapy reported here has 
allowed clear conclusions regarding the long-term 
tolerability of sibenadet therapy. A key design feature of 
this study was the inclusion of a placebo group, which is 
not commonly adopted in long-term safety studies. In 
view of the significant co-morbidity associated with 
COPD, a placebo arm was considered crucial to enable 
effective comparison of AE reporting as well as 
comparison of lung function and HRQL over a significant 
period of time. 
Overall, sibenadet was well tolerated with an AE 
profile comparable with placebo. Not surprisingly, 
predictable ~32-related effects such as tremor, nervous- 
ness and dizziness were seen more frequently in the 
sibenadet group and were commonly cited in patients 
withdrawing from the study due to an AE.Although the 
taste of sibenadet was noted by over 14% of patients in 
the sibenadet group, the unpleasant taste did not result 
in notable patient withdrawal compared with the placebo 
group.The incidence of potential D2-related events was 
low and similar in both groups, providing no evidence of 
systemic D2effects and therefore quelling potential 
concerns over the central nervous system effects of 
dopamine agonists. 
Predictably, respiratory events were the most 
frequently reported AE in both treatment groups. 
Although the incidence of COPD exacerbations was 
similar, respiratory infection was reported with greater 
frequency in the placebo group. Previous sibenadet 
studies have not reflected this finding and interpretation 
of these data is unclear. 
The observed reduction in rescue medication usage 
associated with sibenadet therapy is consistent with the 
bronchodilator properties of this dual agonist. It is 
noteworthy that no deterioration in lung function was 
seen over the course of the study in the sibenadet 
treatment arm. One potential explanation for this 
observation is that patients took study medication prior 
to FEV I measurement.This observation could, however, 
simply represent an anomaly and no conclusions can be 
drawn from this study alone. Investigations of greater 
duration than l year would be necessary to define 
adequately any potential effect of sibenadet on the rate 
of decline in lung function. 
In conclusion, this long-term study has shown 
sibenadet therapy to be well tolerated with few 
differences in the incidence of AEs in comparison with 
placebo, with the exception of known ~2-adrenoceptor 
agonist effects, which occurred more frequently in the 
sibenadet group.While systemic D 2 agonists are known 
to induce nausea, vomiting, dizziness and somnolence, 
the frequencies of these events were low and were 
similar in both treatment groups, showing no evidence of 
centrally mediated D 2 effects with inhaled sibenader. 
While initial clinical evaluation of sibenadet was 
promising (7), the benefits associated with sibenadet 
therapy were not maintained over the course of 
subsequent large-scale clinical studies. Although the 
tolerability profile of sibenadet described in this study is 
compatible with long-term dosing, disappointing efficacy 
findings mean that the development of sibenadet has 
now been discontinued. 
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